Gainers

• Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million.
• Kalaris Therapeutics (NASDAQ:KLRS) shares increased by 18.76% to $5.47. The market value of their outstanding shares is at $109.6 million.
• American Well (NYSE:AMWL) stock increased by 17.07% to $12.82. The company's market cap stands at $182.4 million.
• Alpha Tau Medical (NASDAQ:DRTS) stock moved upwards by 14.81% to $13.64. The market value of their outstanding shares is at $1.0 billion.
• SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 13.94% to $13.39. The market value of their outstanding shares is at $2.3 billion.
• Estrella Immunopharma (NASDAQ:ESLA) stock increased by 13.62% to $0.84. The company's market cap stands at $31.9 million.

Losers

• Agape ATP (NASDAQ:ATPC) shares fell 21.7% to $3.29 during Friday's regular session. The company's market cap stands at $4.2 million.
• Apollomics (NASDAQ:APLM) stock fell 20.93% to $18.4. The market value of their outstanding shares is at $51.1 million.
• Liminatus Pharma (NASDAQ:LIMN) shares decreased by 14.73% to $0.13. The market value of their outstanding shares is at $9.9 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) shares decreased by 12.91% to $3.09. The company's market cap stands at $2.0 million.
• Intuitive Surgical (NASDAQ:ISRG) stock decreased by 12.58% to $351.72. The company's market cap stands at $142.4 billion. The company's, Q2 earnings came out yesterday.
• EUDA Health Holdings (NASDAQ:EUDA) shares decreased by 12.12% to $11.5. The market value of their outstanding shares is at $39.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.